Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655066 in active psoriatic arthritis
NL-OMON44526Phase 2Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of risankizumab in psoriatic arthritis (PsA) (2 arms), sponsored by Boehringer Ingelheim. Planned start Feb 2016; status: withdrawn.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON44526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44526.